Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT05665530
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:34.398468+00:00
Published At
2026-01-26T00:00:00+00:00
Record Updated At
2026-01-26
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Aggressive B-Cell Non-Hodgkin\u0027s Lymphoma (NHL)", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "Mantle Cell Lymphoma (MCL)", "Richter\u0027s Syndrome", "T-cell Lymphoma", "Diffuse Large B-cell Lymphoma (DLBCL)", "Marginal Zone Lymphoma", "Myeloid Malignancies", "Acute Myeloid Leukemia (AML)", "Chronic Myelomonocytic Leukemia (CMML)", "Myelodysplastic Syndrome (MDS)", "MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-01-26"
protocolSection.identificationModule.nctId
"NCT05665530"
protocolSection.identificationModule.officialTitle
"A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With Relapsed/Refractory Hematologic Malignancies"
protocolSection.statusModule.overallStatus
"COMPLETED"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL) (protocolSection.conditionsModule.conditions)
  • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (protocolSection.conditionsModule.conditions)
  • Mantle Cell Lymphoma (MCL) (protocolSection.conditionsModule.conditions)
  • Richter's Syndrome (protocolSection.conditionsModule.conditions)
  • T-cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Diffuse Large B-cell Lymphoma (DLBCL) (protocolSection.conditionsModule.conditions)
  • Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Myeloid Malignancies (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia (AML) (protocolSection.conditionsModule.conditions)
  • Chronic Myelomonocytic Leukemia (CMML) (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome (MDS) (protocolSection.conditionsModule.conditions)
  • MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.